You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

flumatinib

Showing 1 - 14 of 14
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Myeloid Leukemia in Chronic Phase Trial in Shenzhen (Flumatinib, Dasatinib)

Recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg))

Recruiting
  • CML, Chronic Phase
  • Flumatinib mesylate tablets (400mg)
  • Flumatinib mesylate tablets (600mg)
  • Harbin, Hei Longjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
Apr 28, 2022

Flumatinib, Chronic Myeloid Leukemia, Chronic Phase, Imatinib Trial in Shenzhen (Flumatinib)

Recruiting
  • Flumatinib
  • +2 more
  • Flumatinib
  • Shenzhen, Guangdong, China
    The Second People's Hospital of Shenzhen
Mar 15, 2022

CML, Chronic Phase Trial in Harbin (Flumatinib, Imatinib)

Not yet recruiting
  • CML, Chronic Phase
  • Harbin, Heilongjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
May 5, 2022

Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,

Recruiting
  • Philadelphia Chromosome
  • +4 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jun 23, 2022

Acute Lymphocytic Leukemia, Adult B-Cell, BCR-ABL1 Fusion Protein Expression Trial in Nanjing (Flumatinib)

Recruiting
  • Acute Lymphocytic Leukemia, Adult B-Cell
  • BCR-ABL1 Fusion Protein Expression
  • Flumatinib
  • Nanjing, Jiangsu, China
  • +1 more
Mar 22, 2022

New Diagnosed Chronic Phase Chronic Myeloid Leukemia

Recruiting
  • Validity and Safety
    • Guangzhou, Guangdong, China
      NanfangH
    Apr 9, 2022

    Acute Leukemia Trial in Tianjin (Flumatinib, Imatinib)

    Recruiting
    • Acute Leukemia
    • Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Sep 27, 2021

    Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid

    Recruiting
    • CML-CP; Mutation;Suboptimal Response or Failure in TKI
    • Wuhan, Hubei, China
      Weiming Li
    May 31, 2021

    Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase

    Recruiting
    • CML, Chronic Phase; TKI
    • Flumatinib Mesylate
    • Nilotinib Pill
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University, Jiangsu Ins
    Feb 1, 2021

    Treatment Free Remission (TFR) in CML Patients (CML-CP)Study

    Not yet recruiting
    • Chronic Myeloid Leukemia
    • Treatment-free Remission
    • TFR(Treatment-Free Remission)
    • (no location specified)
    Jun 27, 2022

    CML, CML-CP,MMR,TKI Trial in Tianjin (Flumatinib 600mg qd, Imatinib 400mg qd)

    Completed
    • CML, CML-CP,MMR,TKI
    • Flumatinib 600mg qd
    • Imatinib 400mg qd
    • Tianjin, Tianjin, China
      Hospital of Blood Diseases, Chinese Academy of Medical Sciences
    Feb 24, 2018

    Chronic Myelogenous Leukemia Trial in Wuhan (Flumatinib mesylate tablet 600 mg qd)

    Unknown status
    • Chronic Myelogenous Leukemia
    • Flumatinib mesylate tablet 600 mg qd
    • Wuhan, Hubei, China
      Union Hospital Tongji Medical College Huazhong University of Sci
    Jul 29, 2015

    Myelogenous Leukemia, Chronic Trial in China (flumatinib, imatinib)

    Unknown status
    • Myelogenous Leukemia, Chronic
    • Beijing, Beijing, China
    • +4 more
    Apr 9, 2013